We are thrilled to announce that Biocytogen will attend Fierce Biotech Week from May 12th - 14th in Everett, MA. The conference will offer direct access to the leaders and ideas shaping the future of biotech and pharma. Attendees gain practical perspectives on navigating capital constraints, advancing pipelines, and driving operational excellence, alongside opportunities for meaningful, curated networking.
What is Fierce Biotech Week
Fierce Biotech Week brings together 1,400+ attendees, including key decision-makers, for a highly strategic and action-oriented experience focused on today’s most pressing industry challenges. The event is designed for leaders and delivers executive-level insights, real-world case studies, and forward-looking strategies across drug development, clinical operations, business development, and corporate communications.
Event Overview
Date: May 12th - 14th, 2026
Venue: Encore Boston Harbor, 1 Broadway, Everett, MA 02149
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to meeting you in Everett, MA!
